The overall goal of the proposed studies is to determine the role of OC-116 kDa, a newly-described molecule, in osteoclast function and to apply this knowledge to the control of osteolytic diseases. The proposed studies involve an in-depth analysis of the expression, regulation, and function of OC-116 kDa in osteoclastic bone resorption. The hypothesis of the proposed studies is that OC-116 kDa is expressed selectively in osteoclasts; that it constitutes an integral part of the osteoclast proton pump; and that it plays a key functional role in the acidification of the subosteoclastic lacuna.
In Aim 1, the expression of OC-116 kDa will be determined in vivo, using RT-PCR, RNase protection, in situ hybridization and immunochemistry, at the cellular and ultrastructural levels.
In Aim 2, the association of OC-116 kDa as part of the osteoclast proton pump will be determined by coprecipitation of OC-116 kDa with known subunits of the pump, and functionally by antisense inhibition in vitro.
In Aim 3, the function of OC-116 kDa will be established using targeted disruption of the endogenous gene. The effect of the null mutation on phenotype and osteoclast function in embryonic, neonatal and adult mice will be determined.
In Aim 4, the regulation of OC-116 kDa in osteoclasts by stimulators and inhibitors of bone resorption will be assessed. In addition, studies of the mechanisms of cell-specific regulation of OC-116 kDa will be initiated using promoter-reporter transgenic animals.
In Aim 5, specific inhibitors of OC-116 kDa will be sought and their effect on bone resorption determined. By virtue of its selective expression, OC-116 kDa may be useful as a target of specific therapeutic inhibitors of resorption.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE007378-15
Application #
6175863
Study Section
Oral Biology and Medicine Subcommittee 1 (OBM)
Program Officer
Zhang, Guo He
Project Start
1997-07-01
Project End
2002-06-30
Budget Start
2000-07-01
Budget End
2002-06-30
Support Year
15
Fiscal Year
2000
Total Cost
$330,830
Indirect Cost
Name
Forsyth Institute
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02142
Morse, L; Teng, Y D; Pham, L et al. (2008) Spinal cord injury causes rapid osteoclastic resorption and growth plate abnormalities in growing rats (SCI-induced bone loss in growing rats). Osteoporos Int 19:645-52
Battaglino, R A; Pham, L; Morse, L R et al. (2008) NHA-oc/NHA2: a mitochondrial cation-proton antiporter selectively expressed in osteoclasts. Bone 42:180-92
Pham, L; Purcell, P; Morse, L et al. (2007) Expression analysis of nha-oc/NHA2: a novel gene selectively expressed in osteoclasts. Gene Expr Patterns 7:846-51
Schulze-Spate, Ulrike; Battaglino, Ricardo; Fu, Jia et al. (2007) Brn3 transcription factors control terminal osteoclastogenesis. J Cell Biochem 102:1-12
Battaglino, R; Vokes, M; Schulze-Spate, U et al. (2007) Fluoxetine treatment increases trabecular bone formation in mice. J Cell Biochem 100:1387-94
Keles, Ahmet; Grunes, Brandon; Difuria, Catherine et al. (2007) Inhibition of tooth movement by osteoprotegerin vs. pamidronate under conditions of constant orthodontic force. Eur J Oral Sci 115:131-6
Okamatsu, Yoshimasa; Kim, David; Battaglino, Ricardo et al. (2004) MIP-1 gamma promotes receptor-activator-of-NF-kappa-B-ligand-induced osteoclast formation and survival. J Immunol 173:2084-90
Battaglino, R; Kim, D; Fu, J et al. (2002) c-myc is required for osteoclast differentiation. J Bone Miner Res 17:763-73
Deng, W; Stashenko, P; Chen, W et al. (2001) Characterization of mouse Atp6i gene, the gene promoter, and the gene expression. J Bone Miner Res 16:1136-46
Li, Y P; Chen, W; Liang, Y et al. (1999) Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification. Nat Genet 23:447-51

Showing the most recent 10 out of 27 publications